Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Advanced Drainage Systems Inc — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Advanced Drainage Systems Inc trades at $125.03 (market cap $9.56B). The key difference: Advanced Drainage Systems Inc is the larger of the two by market cap, and Advanced Drainage Systems Inc pays a 0.63% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Advanced Drainage Systems Inc for 43 Days on average.
| SYRE | WMS | |
|---|---|---|
Market Cap | $7.52B | $9.56B |
Volume | 1,441,031 | 716,757 |
Sector | Health | Basic Materials |
52-Week High | $108.92 | $175.38 |
52-Week Low | $22.18 | $125.19 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $6.52B | $11.16B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Advanced Drainage Systems (WMS) trades at $125.19, down 0.59% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $2.49 beating estimates of $2.10. Revenue remains stable at $2.90B for 2025, while profitability metrics show robust ROE of 24.9% and net margin of 14%. Recent news highlights institutional buying activity and the release of Q1 2027 results showing 21% revenue growth.
WMS presents a compelling investment case with strong fundamentals and analyst consensus pointing to significant upside potential (target $188.20). However, near-term technical weakness and projected negative cash flow in 2026 warrant caution. The stock offers exposure to water infrastructure growth but faces execution risks from recent acquisitions and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
